RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial

被引：1

作者：

Johnson, M. L. ^{[1
]}

Langdon, R. ^{[2
]}

Ellison, D. ^{[3
]}

Spira, A. ^{[4
]}

Amin, H. ^{[5
]}

Castine, M. ^{[6
]}

Daniel, D. B. ^{[7
]}

Sohoni, S. ^{[8
]}

Chen, Y-C. ^{[8
]}

Hayes, J. ^{[8
]}

Mu, Y. ^{[8
]}

Masciari, S. ^{[9
]}

Wang, X. ^{[8
]}

Toya, S. ^{[10
]}

机构：

[1] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA

[2] Nebraska Canc Specialists, Omaha, NE USA

[3] Charleston Oncol PA, Charleston, SC USA

[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA

[5] Boca Raton Clin Res Associates Inc, Plantation, FL USA

[6] Hematol Oncol Clin, Baton Rouge, LA USA

[7] Sarah Cannon Res Inst Tennessee Oncol, Chattanooga, TN USA

[8] Revolut Med, Redwood City, CA USA

[9] Sanofi, Cambridge, MA USA

[10] GenHarp Clin Solut LLC, Evergreen Pk, IL USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.02.085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

76TiP

引用

页码：S66 / S67

页数：2

共 50 条

[41] A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results
Janne, Pasi A.
Reckamp, Karen
Koczywas, Marianna
Camidge, David R.
Engelman, Jeffery A.
Khuri, Fadlo
Rajan, Arun
Gadgeel, Shirish
Taylor, Ian
Liang, Jane
O'Connell, Joseph
Giaccone, Giuseppe
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S293 - S294
[42] Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT)
Boyer, M. J.
Blackhall, F. H.
Park, K.
Barrios, C. H.
Krzakowski, M. J.
Taylor, I.
Liang, J. Q.
Denis, L. J.
O'Connell, J. P.
Ramalingam, S. S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[43] E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
Argiris, A.
Lee, J.
Schiller, J. H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[44] A phase II trial investigating the highly selective c-Met inhibitor tepotinib in stage IIIB/IV lung adenocarcinoma with MET exon 14 alterations after failure of at least one prior therapy
Paik, P. K.
Stammberger, U.
Bruns, R.
ANNALS OF ONCOLOGY, 2016, 27
[45] PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)
Campbell, A.
Reckamp, K. L.
Camidge, D. R.
Giaccone, G.
Gadgeel, S. M.
Khuri, F. R.
Engelman, J. A.
Denis, L. J.
O'Connell, J. P.
Janne, P. A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[46] Pharmacokinetic (PK) - pharmacodynamic (PD) study of gemcitabine (G) in a randomised phase II trial of carboplatin (C) combined with G at standard rate infusion or fixed dose rate infusion in patients with advanced non-small-cell lung cancer (NSCLC).
Soo, RA
Lim, HL
Wang, LZ
Tham, LS
Soong, R
Lee, HS
Liang, S
Lee, SC
Boyer, M
Goh, BC
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 141S - 141S
[47] Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
Goldman, Jonathan W.
Horinouchi, Hidehito
Cho, Byoung Chul
Tomasini, Pascale
Dunbar, Martin
Hoffman, David
Parikh, Apurvasena
Blot, Vincent
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Biomarker evaluation in the phase III, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes
Herbst, Roy S.
Stern, Howard
Amler, Lukas
Otterson, Gregory
Lin, Ming
O'Connor, Paula
Hainsworth, John
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S323 - S323
[49] Biomarker evaluation in the Phase Ill, placebo (P)-controlled, randomized BeTa trial of bevacizumab (B) and erlotinib (E) for patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of standard 1st-line chemotherapy: correlation with treatment outcomes
Herbst, Roy
Stern, Howard
Amler, Lukas
Otterson, Gregory
Lin, Ming
O'Connor, Paula
Hainsworth, John
CANCER RESEARCH, 2009, 69
[50] Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy
Otterson, G. A.
O'Connor, P. G.
Lin, M.
Herbst, R. S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →